Compagnie Lombard Odier SCmA’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-560
| Closed | -$51.7K | – | 479 |
|
|
2024
Q4 | $51.7K | Buy |
560
+529
| +1,706% | +$47.6K | ﹤0.01% | 332 |
|
|
2024
Q3 | $2.6K | Sell |
31
-1,219
| -98% | -$93K | ﹤0.01% | 436 |
|
|
2024
Q2 | $85.8K | Hold |
1,250
| – | – | ﹤0.01% | 296 |
|
|
2024
Q1 | $91.6K | Sell |
1,250
-45,410
| -97% | -$3.49M | ﹤0.01% | 314 |
|
|
2023
Q4 | $3.78M | Buy |
46,660
+42,851
| +1,125% | +$3.33M | 0.07% | 118 |
|
|
2023
Q3 | $285K | Sell |
3,809
-29,477
| -89% | -$2.27M | 0.01% | 226 |
|
|
2023
Q2 | $2.57M | Sell |
33,286
-1,708
| -5% | -$136K | 0.07% | 105 |
|
|
2023
Q1 | $2.9M | Sell |
34,994
-1,202
| -3% | -$99.6K | 0.07% | 108 |
|
|
2022
Q4 | $3.11M | Buy |
36,196
+3,047
| +9% | +$241K | 0.08% | 105 |
|
|
2022
Q3 | $2.04M | Sell |
33,149
-505
| -2% | -$31.8K | 0.06% | 115 |
|
|
2022
Q2 | $2.08M | Sell |
33,654
-833
| -2% | -$51.6K | 0.05% | 115 |
|
|
2022
Q1 | $2.05M | Sell |
34,487
-3,038
| -8% | -$194K | 0.04% | 120 |
|
|
2021
Q4 | $2.72M | Sell |
37,525
-950
| -2% | -$65.4K | 0.05% | 110 |
|
|
2021
Q3 | $2.69M | Sell |
38,475
-2,400
| -6% | -$169K | 0.06% | 115 |
|
|
2021
Q2 | $2.81M | Buy |
40,875
+2,166
| +6% | +$145K | 0.06% | 106 |
|
|
2021
Q1 | $2.5M | Buy |
38,709
+1,653
| +4% | +$107K | 0.06% | 147 |
|
|
2020
Q4 | $2.16M | Buy |
37,056
+346
| +0.9% | +$20.9K | 0.06% | 116 |
|
|
2020
Q3 | $2.32M | Sell |
36,710
-3,750
| -9% | -$260K | 0.07% | 105 |
|
|
2020
Q2 | $3.11M | Buy |
40,460
+460
| +1% | +$35.3K | 0.1% | 86 |
|
|
2020
Q1 | $2.99M | Sell |
40,000
-9,160
| -19% | -$633K | 0.13% | 83 |
|
|
2019
Q4 | $3.19M | Buy |
49,160
+23,981
| +95% | +$1.56M | 0.12% | 83 |
|
|
2019
Q3 | $1.59M | Buy |
25,179
+600
| +2% | +$39.2K | 0.07% | 108 |
|
|
2019
Q2 | $1.66M | Sell |
24,579
-4,095
| -14% | -$269K | 0.07% | 115 |
|
|
2019
Q1 | $1.87M | Sell |
28,674
-79,200
| -73% | -$5.26M | 0.08% | 116 |
|
|
2018
Q4 | $6.75M | Buy |
107,874
+414
| +0.4% | +$28.9K | 0.28% | 69 |
|
|
2018
Q3 | $8.3M | Buy |
107,460
+3,084
| +3% | +$233K | 0.29% | 70 |
|
|
2018
Q2 | $7.4M | Sell |
104,376
-4,313
| -4% | -$305K | 0.27% | 72 |
|
|
2018
Q1 | $8.19M | Sell |
108,689
-149,727
| -58% | -$11.9M | 0.3% | 66 |
|
|
2017
Q4 | $18.5M | Buy |
258,416
+83,957
| +48% | +$6.38M | 0.33% | 63 |
|
|
2017
Q3 | $14.1M | Sell |
174,459
-39,448
| -18% | -$3.02M | 0.5% | 52 |
|
|
2017
Q2 | $15.1M | Sell |
213,907
-49,258
| -19% | -$3.28M | 0.52% | 46 |
|
|
2017
Q1 | $17.9M | Sell |
263,165
-587,547
| -69% | -$41.3M | 0.6% | 42 |
|
|
2016
Q4 | $60.9M | Buy |
850,712
+13,043
| +2% | +$969K | 1.78% | 13 |
|
|
2016
Q3 | $66.3M | Buy |
837,669
+103,044
| +14% | +$8.37M | 1.93% | 11 |
|
|
2016
Q2 | $61.3M | Buy |
734,625
+251,940
| +52% | +$22.4M | 1.78% | 13 |
|
|
2016
Q1 | $44.4M | Buy |
482,685
+54,214
| +13% | +$4.89M | 1.36% | 18 |
|
|
2015
Q4 | $43.4M | Buy |
428,471
+54,331
| +15% | +$5.65M | 1.36% | 19 |
|
|
2015
Q3 | $36.7M | Buy |
374,140
+35,161
| +10% | +$3.91M | 1.5% | 17 |
|
|
2015
Q2 | $39.7M | Sell |
338,979
-8,544
| -2% | -$934K | 1.48% | 18 |
|
|
2015
Q1 | $34.1M | Sell |
347,523
-559,122
| -62% | -$56.8M | 1.28% | 21 |
|
|
2014
Q4 | $85.5M | Sell |
906,645
-825,679
| -48% | -$85.4M | 3.94% | 4 |
|
|
2014
Q3 | $184M | Sell |
1,732,324
-264,951
| -13% | -$25.9M | 7.44% | 1 |
|
|
2014
Q2 | $166M | Buy |
1,997,275
+616,706
| +45% | +$48M | 6.58% | 1 |
|
|
2014
Q1 | $97.8M | Buy |
1,380,569
+662,315
| +92% | +$51.9M | 4.06% | 3 |
|
|
2013
Q4 | $54M | Buy |
+718,254
| New | +$50M | 2.27% | 12 |
|
Other funds holding GILD
Compagnie Lombard Odier SCmA's GILD Position: Q1 2025 in Review
Compagnie Lombard Odier SCmA sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 560 shares — an estimated $51.7K sold.
Compagnie Lombard Odier SCmA first reported a position in GILD in Q4 2013 and held it in 45 quarters. The position peaked at $184M in Q3 2014. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.
- Compagnie Lombard Odier SCmA reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 560 Gilead Sciences shares in Q1 2025, an estimated $51.7K.
- Compagnie Lombard Odier SCmA first reported a position in Gilead Sciences in Q4 2013 and held it in 45 quarters.
- Compagnie Lombard Odier SCmA's Gilead Sciences position peaked at $184M in Q3 2014.
- 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2025, filed 16 Apr 2025.